Pulmonary arterial hypertension (PAH) is responsible for the premature death mainly
because of progressive and severe heart failure. This disease is characterized by increased
pulmonary vascular tone, inflammatory cell infiltration, vascular remodeling and occlusion of
vessels with thrombi, frequently leading to right heart failure. Aiming to better comprehend
the complexity of PAH and find novel therapeutic strategies or improve the existing ones, a
variety of preclinical models have emerged. Although there is no ideal preclinical model of …